On ECHEMI
Home > Drugs > Tricuspid atresia
Tricuspid atresia
In 1987, Kreysig first clearly described the anatomical features of tricuspid atresia, namely the lack of direct communication between the right ventricle and the right atrium. In 1861, Schuberg first used the term tricuspid atresia to describe this malformation. Although several cases were reported in English literature in the 19th century, it was not until 1917 that Hess officially adopted the term tricuspid atresia in the literature. In 1906, Kuhen reported that the great arteries of patients with tricuspid atresia could be normal or transposed. Tricuspid atresia is a cyanotic congenital heart disease with an incidence of about 1-5% of congenital heart diseases. It ranks third among cyanotic congenital heart diseases after tetralogy of Fallot and transposition of the great arteries. The main pathological changes are tricuspid atresia or absence of the tricuspid valve orifice, patent foramen ovale or atrial septal defect, mitral valve and left ventricular hypertrophy, and right ventricular hypoplasia.
  • Site of disease:

    heart
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    squatting phenomenon distended jugular veins high pulmonary blood flow continuous machine-like murmurs cyanosis of newborns
  • Concurrent disease:

Related Drugs
Nitroglycerin tablets
Indication: It is used for the treatment and prevention of angina pectoris caused by coronary heart disease, and can also be used to lower blood pressure or treat congestive heart failure.
Manufacturer:

Lesheng Pharmaceutical Shijiazhuang Co., Ltd.

Homoharringtonine Sodium Chloride Injection
Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.
Manufacturer:

Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.